RECENT NEWS

The new Moderna Innovation and Technology Centre, which will develop and manufacture mRNA vaccines, has been officially opened by Health and Social Care Secretary Wes Streeting.

Alpenglow Biosciences, a leader in AI-powered 3D pathology, has announced a strategic agreement with Virdx, a biophysics AI company focused on MRI-based cancer detection, with the two firms collaborating to accelerate the development of tools that bridge radiology and pathology.

The International Association for the Study of Lung Cancer (IASLC) Pathology Committee has proposed a simple, prognostically relevant grading system for resected invasive LUSC based on tumour budding, in a newly published study.

Pathways to Antimicrobial Clinical Efficacy (PACE) has recently launched its third funding round, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to global health.

Ataraxis AI, a frontier laboratory developing artificial intelligence–powered prognostic tools for oncology, and Medica Scientia Innovation Research (MEDSIR), a global leader in oncology research, have announced a strategic collaboration to integrate AI into multiple major international trials.

The time it takes to approve clinical trials in the UK has been cut by more than half – from an average of 91 days to just 41 days – following major reforms backed by new digital platforms at the Medicines and Healthcare products Regulatory Agency (MHRA), new research has confirmed.

Breath biopsy firm Owlstone Medical has announced that it has won an award of up to $49.1 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop its POSEIDON programme to enable accurate, low-cost, accessible cancer screening.

The UK Sepsis Trust has commissioned and is fully funding a new study, led by the University of St Andrews, which aims to improve sepsis diagnosis and lead to lifesaving interventions.

Swedish firm Inify Laboratories, which offers prostate cancer diagnostics, has chosen Milton Park in Oxfordshire as the site for its first UK laboratory.

Revvity has announced a programme for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi, as well as a new laboratory-developed test to expand clinical testing for early-stage disease screening.

Proscia is introducing virtual staining in its Concentriq software platform to help laboratories reduce the costs associated with traditional chemical methods and drive efficiency in high-throughput workflows.

A pioneering ‘cloud-based’ AI research screening platform, funded by the National Institute for Health and Care Research (NIHR) will enable NHS trusts across the country to join Al trials aiming to help speed up diagnosis.

The Department of Health and Social Care says the NHS will move from a ‘cheapest-first’ to a ‘patient-first’ approach to purchasing medical technology, as it aims to cut waiting lists and save money in the long term.

The Ecosystem for Pathology Diagnostics with AI Assistance (EMPAIA), an international organisation that advances the use of validated AI solutions in clinical practice, has announced that Epredia has won three categories in the ISB awards.

Lunit a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, has announced a strategic partnership with CellCarta, a globally recognised provider of CRO laboratory services for pharmaceutical research and development.

Aminur Khan, Country Lead UK and Ireland, Beckman Coulter Diagnostics tells Pathology in Practice about his company's presence at Congress and what to expect in the future.

The NHS should get quicker access to the latest AI tools, thanks to a new National Commission that has been tasked with advising the Medicines and Healthcare products Regulatory Agency (MHRA) on how to re-write the regulatory rulebook on AI in healthcare, which will be published next year.

Leica Biosystems and Florida-based Moffitt Cancer Center, one of the USA’s top cancer hospitals and a leader in cancer research, have announced an expansion of their partnership to accelerate the adoption of digital pathology across the state.

Life sciences firm Promega UK has announced the launch of a new programme of Continuing Professional Development (CPD) courses, designed to support those working in the clinical field of life sciences including biomedical scientists, pathologists, and life-sciences researchers.

IBMS President Joanna Andrew talks to Pathology in Practice at Congress 2025.